Company Overview and News

0
Hindustan Copper (₹73.4): Buy

2018-06-12 premium.thehindubusinessline
The stock of Hindustan Copper was on limelight on Tuesday, as the stock jumped 4.4 per cent accompanied with an above average volume. This rally has decisively breached the 21- and 50-day moving average resistances. Investors with a short-term view can buy the stock at current levels.
HINDCOPPER 513599

0
Hindustan Copper aims for ₹2,000 crore turnover

2018-06-05 livemint
Kolkata: State-owned miner Hindustan Copper Ltd was looking to ramp up its smelting capacity to 100,000 tonne per annum from the existing 70,000 tonnes, besides targeting a turnover of ₹2,000 crore by the end of this fiscal year.
HINDCOPPER 513599

0
HCL hopes to cross Rs 2,000 crore turnover in Fiscal Year 2019

2018-06-05 freepressjournal.in
Kolkata: State-run copper producer Hindustan Copper Limited (HCL), which is focusing on exploration in order to assess copper reserve in its mines, on Tuesday said it is expecting its turnover to cross Rs 2,000 crore in the current fiscal, an official said on Tuesday. “We have started an ambitious project on exploration. As of today, we are not exploring beyond an average 500 metre depth. We are not fully aware of our potential in terms of copper reserves available in our mines… We are going to take exploration in a big way.
HINDCOPPER 513599

0
Hind Copper aims Rs 2000 crore revenue in FY#39;19

2018-06-05 moneycontrol
The Hindustan Copper Ltd today said it was aiming Rs 2,000 crore revenue in the current fiscal while, efforts to create wealth from waste will add to Rs 50 crore directly to its bottomline.
HINDCOPPER 513599

0
HCL gets nod to carry own exploration, FY19#39; capex at Rs 700cr

2018-06-05 moneycontrol
State owned Hindustan Copper has received government nod to become an independent copper exploration agency that would give a push to its mining expansion ambitions, a top company official said.
HINDCOPPER 513599

28
Closing Bell: Sensex up 416 pts, Nifty ends May series above 10,700; HDFC Bank leads

2018-05-31 moneycontrol
Fundraising: Multiplex operator PVR is evaluating acquisition opportunities of cinema exhibition chains and plans to raise funds to carry out the transaction through issuance of non convertible debentures (NCDs).
IOC SUZLON ARCHIDPLY CAPF TCHQY 532755 532710 532400 KPIT TORNTPOWER 500570 SUEL CLNDY EVSJF 530965 532667 TECHM 532994 500182 500180 520051 KOTAKBANK 534809 PCJEWELLER COALINDIA HINDCOPPER 532938 532779 533278 532541 532187 HDFCBANK HEROMOTOCO SADBHAV TATAMOTORS NIITTECH ESI INDUSINDBK KMBKY IBN 513599 539207 ICICIBANK HDB 532174 JAMNAAUTO HRTQY 500247 MANPASAND TTM

0
Sterlite plant closure may turn India into copper importer

2018-05-31 moneycontrol
The closure of the Sterlite Copper plant in Thoothukudi (Tuticorin), Tamil Nadu, would increase domestic supply crunch and may turn India into a net importer of primary copper, according to a Cogencis report.
HNDNF HINDCOPPER HINDALCO 513599 500440

0
Hindustan Copper Ltd - Financial Result Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HINDCOPPER 513599

0
Hindustan Copper Ltd - Dividend

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HINDCOPPER 513599

17
The difficulty of being Anil Agarwal: Of controversies and battlegrounds

2018-05-29 moneycontrol
Starting as a scrap dealer, Agarwal built a mining empire turning around government-owned enterprises, setting up facilities in places where bigger names feared to tread and taking bets that others initially scoffed at, and later grudgingly admired. His Vedanta Resources was the first Indian company to list on London Stock Exchange, and Agarwal announced his arrival on the global scene with a palatial house at Mayfair, the tony neighbourhood in the UK capital.
HINDCOPPER RTPPF VED RIO RIO RIO RTNTF LNSTY 513599

1
News In Numbers: Vedanta India’s Sterlite plant in Tuticorin produces 400,000 tonnes of copper annually

2018-05-29 livemint
What is it? The replacement rate of Voter Verifiable Paper Audit Trail (VVPAT) device in Kairana Lok Sabha elections held on Monday.
HINDCOPPER 513599 SBAZ

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...